| Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. | |
| | |
MedLine Citation:
|
PMID: 21474379 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Although low-grade gliomas (LGG) have a less aggressive course than do high-grade gliomas, the outcome of these tumours is ultimately fatal in most patients. Both the tumour and its treatment can cause disabling morbidity, particularly of cognitive functions. Because many patients present with seizures only, with no other signs and symptoms, maintenance of quality of life and function constitutes a particular challenge in LGG. The slow growth pattern of most LGG, and the rare radiological true responses despite a favourable clinical response to treatment, interferes with the use of progression-free survival as the primary endpoint in trials. Overall survival as an endpoint brings logistical challenges, and is sensitive to other non-investigational salvage therapies. Clinical trials for LGG need to consider other measures of patient benefit such as cognition, symptom burden, and seizure activity, to establish whether improved survival is reflected in prolonged wellbeing. This Review investigates clinical and imaging endpoints in trials of LGG, and provides response assessment in neuro-oncology (RANO) criteria for non-enhancing tumours. Additionally, other measures for patients with brain tumours that assess outcome are described. Similar considerations are relevant for trials of high-grade gliomas, although for these tumours survival is shorter and survival endpoints generally have more value than they do for LGG. |
| | |
Authors:
|
Mj van den Bent; Js Wefel; D Schiff; Mjb Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; Ad Waldman; T Gorlia; M Chamberlain; Bg Baumert; Ma Vogelbaum; Dr Macdonald; DA Reardon; Py Wen; Sm Chang; Ah Jacobs |
Related Documents
:
|
21994209 - The prognosis of patients with primary osteosarcoma who have undergone unplanned therapy. 2845769 - Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, ... 232239 - Combination radiotherapy and chemotherapy for small cell carcinoma of the lung. 3894589 - Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the ce... 1587289 - Phase ii study of mitomycin c and 5 fluorouracil in platinum resistant ovarian cancer. 10472359 - Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose seq... 22655249 - Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer:... 8784309 - Incidence and predictors of axillary metastasis in t1 carcinoma of the breast. 17195909 - Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian c... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-4-5 |
Journal Detail:
|
Title: The lancet oncology Volume: - ISSN: 1474-5488 ISO Abbreviation: - Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-4-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100957246 Medline TA: Lancet Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Neuro-Oncology Unit, Daniel den Hoed Cancer Center/Erasmus University Hospital Rotterdam, Rotterdam, Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Injury risk factors in young soccer players detected by a multivariate survival model.
Next Document: Identity crisis? The need for systematic gene IDs.